Cargando…
Upregulation of SATB1 is associated with the development and progression of glioma
BACKGROUND: Special AT-rich sequence-binding protein-1 (SATB1) has been reported to be expressed in several human cancers and may have malignant potential. This study was aimed at investigating the expression and potential role of SATB1 in human glioma. METHOD: The relationship between SATB1 express...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492129/ https://www.ncbi.nlm.nih.gov/pubmed/22839214 http://dx.doi.org/10.1186/1479-5876-10-149 |
_version_ | 1782249063541899264 |
---|---|
author | Chu, Sheng-Hua Ma, Yan-Bin Feng, Dong-Fu Zhang, Hong Zhu, Zhi-An Li, Zhi-Qiang Jiang, Pu-Cha |
author_facet | Chu, Sheng-Hua Ma, Yan-Bin Feng, Dong-Fu Zhang, Hong Zhu, Zhi-An Li, Zhi-Qiang Jiang, Pu-Cha |
author_sort | Chu, Sheng-Hua |
collection | PubMed |
description | BACKGROUND: Special AT-rich sequence-binding protein-1 (SATB1) has been reported to be expressed in several human cancers and may have malignant potential. This study was aimed at investigating the expression and potential role of SATB1 in human glioma. METHOD: The relationship between SATB1 expression, clinicopathological parameters, Ki67 expression and MGMT promoter methylation status was evaluated, and the prognostic value of SATB1 expression in patients with gliomas was analyzed. SATB1-specific shRNA sequences were synthesized, and U251 cells were transfected with SATB1 RNAi plasmids. Expression of SATB1 mRNA and protein was investigated by RT-PCR and immunofluoresence staining and western blotting. The expression of c-Met, SLC22A18, caspase-3 and bcl-2 protein was determined by western blotting. U251 cell growth and adherence was detected by methyl thiazole tetrazolium assay. The apoptosis of U251 cells was examined with a flow cytometer. The adherence, invasion, and in vitro angiogenesis assays of U251 cells were done. The growth and angiogenesis of SATB1 low expressing U251 cells was measured in an in vivo xenograft model. RESULTS: Of 70 tumors, 44 (62.9%) were positive for SATB1 expression. SATB1 expression was significantly associated with a high histological grade and with poor survival in univariate and multivariate analyses. SATB1 expression was also positively correlated with Ki67 expression but negatively with MGMT promoter methylation in glioma tissues. SATB1 shRNA expression vectors could efficiently induce the expression of SLC22A18 protein, increase the caspase-3 protein, inhibit the expression of SATB1, c-Met and bcl-2 protein, the growth, invasion, metastasis and angiogenesis of U251 cells, and induce apoptosis in vitro. Furthermore, the tumor growth of U251 cells expressing SATB1 shRNA were inhibited in vivo, and immunohistochemical analyses of tumor sections revealed a decreased vessel density in the animals where shRNA against SATB1 were expressed. CONCLUSIONS: SATB1 may have an important role as a positive regulator of glioma development and progression, and that SATB1 might be a useful molecular marker for predicting the prognosis of glioma. |
format | Online Article Text |
id | pubmed-3492129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34921292012-11-08 Upregulation of SATB1 is associated with the development and progression of glioma Chu, Sheng-Hua Ma, Yan-Bin Feng, Dong-Fu Zhang, Hong Zhu, Zhi-An Li, Zhi-Qiang Jiang, Pu-Cha J Transl Med Research BACKGROUND: Special AT-rich sequence-binding protein-1 (SATB1) has been reported to be expressed in several human cancers and may have malignant potential. This study was aimed at investigating the expression and potential role of SATB1 in human glioma. METHOD: The relationship between SATB1 expression, clinicopathological parameters, Ki67 expression and MGMT promoter methylation status was evaluated, and the prognostic value of SATB1 expression in patients with gliomas was analyzed. SATB1-specific shRNA sequences were synthesized, and U251 cells were transfected with SATB1 RNAi plasmids. Expression of SATB1 mRNA and protein was investigated by RT-PCR and immunofluoresence staining and western blotting. The expression of c-Met, SLC22A18, caspase-3 and bcl-2 protein was determined by western blotting. U251 cell growth and adherence was detected by methyl thiazole tetrazolium assay. The apoptosis of U251 cells was examined with a flow cytometer. The adherence, invasion, and in vitro angiogenesis assays of U251 cells were done. The growth and angiogenesis of SATB1 low expressing U251 cells was measured in an in vivo xenograft model. RESULTS: Of 70 tumors, 44 (62.9%) were positive for SATB1 expression. SATB1 expression was significantly associated with a high histological grade and with poor survival in univariate and multivariate analyses. SATB1 expression was also positively correlated with Ki67 expression but negatively with MGMT promoter methylation in glioma tissues. SATB1 shRNA expression vectors could efficiently induce the expression of SLC22A18 protein, increase the caspase-3 protein, inhibit the expression of SATB1, c-Met and bcl-2 protein, the growth, invasion, metastasis and angiogenesis of U251 cells, and induce apoptosis in vitro. Furthermore, the tumor growth of U251 cells expressing SATB1 shRNA were inhibited in vivo, and immunohistochemical analyses of tumor sections revealed a decreased vessel density in the animals where shRNA against SATB1 were expressed. CONCLUSIONS: SATB1 may have an important role as a positive regulator of glioma development and progression, and that SATB1 might be a useful molecular marker for predicting the prognosis of glioma. BioMed Central 2012-07-28 /pmc/articles/PMC3492129/ /pubmed/22839214 http://dx.doi.org/10.1186/1479-5876-10-149 Text en Copyright ©2012 Chu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Chu, Sheng-Hua Ma, Yan-Bin Feng, Dong-Fu Zhang, Hong Zhu, Zhi-An Li, Zhi-Qiang Jiang, Pu-Cha Upregulation of SATB1 is associated with the development and progression of glioma |
title | Upregulation of SATB1 is associated with the development and progression of glioma |
title_full | Upregulation of SATB1 is associated with the development and progression of glioma |
title_fullStr | Upregulation of SATB1 is associated with the development and progression of glioma |
title_full_unstemmed | Upregulation of SATB1 is associated with the development and progression of glioma |
title_short | Upregulation of SATB1 is associated with the development and progression of glioma |
title_sort | upregulation of satb1 is associated with the development and progression of glioma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492129/ https://www.ncbi.nlm.nih.gov/pubmed/22839214 http://dx.doi.org/10.1186/1479-5876-10-149 |
work_keys_str_mv | AT chushenghua upregulationofsatb1isassociatedwiththedevelopmentandprogressionofglioma AT mayanbin upregulationofsatb1isassociatedwiththedevelopmentandprogressionofglioma AT fengdongfu upregulationofsatb1isassociatedwiththedevelopmentandprogressionofglioma AT zhanghong upregulationofsatb1isassociatedwiththedevelopmentandprogressionofglioma AT zhuzhian upregulationofsatb1isassociatedwiththedevelopmentandprogressionofglioma AT lizhiqiang upregulationofsatb1isassociatedwiththedevelopmentandprogressionofglioma AT jiangpucha upregulationofsatb1isassociatedwiththedevelopmentandprogressionofglioma |